Cristiana Campa | CMC External Intelligence and Innovation Lead, Drug Development and Supply
GSK

Cristiana Campa is CMC External Intelligence and Innovation Lead, Drug Development and Supply, at GSK. She brings more than 20 years’ experience in Chemistry, Manufacturing and Control (CMC) for biologics R&D and actively fosters dialogue with industry peers and regulatory agencies on innovative technologies, specification setting, stability, accelerated development strategies, and pandemic preparedness. Her external leadership roles include membership of the PDA Board of Directors (since 2023), EFPIA lead in the ICH Expert Working Group revising ICH Q6 (since 2024), co-chair of the PDA Vaccine Interest Group, chair of the Vaccines Europe/IFPMA CMC Adaptive Pathways team (formerly the COVAX support team), and membership of the US Pharmacopeia Vaccines Expert Committee for the 2025–2030 cycle. Cristiana earned a PhD and completed postdoctoral work in Chemistry. She began her career at Bracco Imaging SpA, advancing from senior researcher to head of the Trieste research laboratory. In 2006 she joined Novartis Vaccines as Analytical Senior Manager and later Head of Analytical Development, Italy. After GSK acquired Novartis Vaccines in 2015, she served as Head of Quality by Design Integration and, until June 2018, Head of Science and Development Practices in Global Technical R&D (covering Quality by Design, Knowledge Management, and development roadmaps). Until February 2025 she was Global Vaccines Technical R&D Advisor at GSK, and subsequently CMC External Intelligence Lead in Vaccines Technical R&D at GSK.